WuXi Biologics’ Innovative Bispecific Platform WuXiBody Secures US Patent
WuXi Biologics (HKG: 2269), a leading China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has...
Drug Farm’s DF-003 Earns FDA Rare Pediatric Disease Designation for ROSAH Syndrome
Sino-US biotech company Drug Farm has announced that it has received Rare Pediatric Disease Designation...
SciClone Pharmaceuticals Teams Up with SPH Health and Hi Dr to Launch Internet Hospital in China
SciClone Pharmaceuticals Inc., (HKG: 6600), a prominent player in China’s pharmaceutical industry, has joined forces...
Zuellig Pharma Partners with Substipharm Biologics for Japanese Encephalitis Vaccine Distribution
Singapore-based healthcare company Zuellig Pharma has announced the establishment of a commercialization partnership with France-based...
XtalPi Forms Strategic Partnership with ABB Robotics to Automate Lab Workstations in China
Sino-US AI drug development company XtalPi (QuantumPharm, HKG: 2228) has entered into a strategic partnership...
InnoCare Pharma Receives US FDA IND Approval for BCL2 Inhibitor ICP-248
InnoCare Pharma (HKG: 9969; SHA: 688428), a China-based pharmaceutical company, has announced that it has...
Chipscreen NewWay Biosciences Initiates Phase I Trial for PD-1/CD40 Bispecific Antibody Candidate NWY001
China-based Chengdu Chipscreen NewWay Biosciences Co., Ltd has announced that the first patient has been...
Mindray Partners with WakeMed for Comprehensive Patient Monitoring Solutions
Shenzhen-based medtech company Mindray has announced a procurement agreement with WakeMed Health & Hospitals in...
3D Medicines Secures Registration for Envafolimab in Macau for Advanced Solid Tumors
3D Medicines (HKG: 1244), a China-based oncology specialist, has announced the registration of its PD-L1...
Hope Medicine Initiates Phase II Trial for HMI-115 in Endometriosis Treatment
Hope Medicine Inc., based in China, has announced the first patient dosing in a global...
Neuboron Medtech Secures Clinical Trial Approval for First BNCT Drug in China
Neuboron Medtech Ltd., based in China, has received clinical trial approval for its borofalan (10b)...
AstraZeneca China Announces Leadership Changes and New Biopharmaceutical Unit
AstraZeneca (AZ, NASDAQ: AZN)’s China unit is set to undergo significant organizational changes, including the...
SciClone’s Partner Menarini Files for Elacestrant Approval in Macau for Advanced Breast Cancer
SciClone Pharmaceuticals Inc. (HKG: 6600) has announced that its Italian partner, Menarini Group, has submitted...
China’s State Council Unveils 26 Initiatives to Enhance Grey-hair Economy
The State Council has unveiled the “Opinions on Developing the Grey-hair Economy to Boost Wellbeing...
China Grand Pharma to Acquire 63% Stake in Duoputai for RMB 442 Million
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced its intention to...
Bayer’s Asklepios BioPharmaceutical Launches Phase II Trial for AAV Therapy in Heart Failure
Bayer’s (ETR: BAYN) gene therapy subsidiary, Asklepios BioPharmaceutical, has initiated patient recruitment for a Phase...
CanSino Biologics Enrolls First Patient in Phase I Trial of Innovative Polio Vaccine
CanSino Biologics (SHA: 688185, HKG: 6185), a China-based biotechnology firm, has announced the enrollment of...
Novartis Acquires Calypso Biotech for USD 250 Million to Bolster IL-15 Pipeline
Novartis (NYSE: NVS) has finalized an agreement to acquire Netherlands-based Calypso Biotech, a 2013 spinout...
Cytokinetics Attracts Big Pharma Interest Amid Aficamten’s Phase III Success
Cytokinetics (NASDAQ: CYTK), a specialist in cardiovascular diseases, is reportedly attracting interest from multiple Big...
RemeGen Secures Fast-Track Designation for RC88 in Platinum-Resistant Ovarian Cancer
China-based biotech RemeGen Co., Ltd (HKG: 9995; SHA: 688331) has received fast-track designation (FTD) from...